|1.||Gieselmann, Volkmar: 27 articles (09/2015 - 01/2003)|
|2.||Gieselmann, V: 14 articles (02/2010 - 03/2000)|
|3.||Matzner, Ulrich: 11 articles (09/2015 - 01/2005)|
|4.||Eckhardt, Matthias: 8 articles (09/2015 - 06/2006)|
|5.||Fogh, Jens: 7 articles (06/2012 - 05/2005)|
|6.||Lüllmann-Rauch, R: 7 articles (01/2006 - 05/2001)|
|7.||D'Hooge, Rudi: 6 articles (07/2015 - 09/2007)|
|8.||Lüllmann-Rauch, Renate: 6 articles (09/2011 - 05/2005)|
|9.||Matzner, U: 6 articles (01/2006 - 05/2000)|
|10.||Stroobants, Stijn: 5 articles (07/2015 - 06/2008)|
|1.||Metachromatic Leukodystrophy (Sulfatide Lipidosis)
07/01/1972 - "An improved method for the determination of leukocyte arylsulfatase A and its application to the diagnosis of metachromatic leukodystrophy in homozygous and heterozygous states."
05/20/2011 - "Preclinical studies in mouse models of metachromatic leukodystrophy, however, showed that arylsulfatase A (ASA) is able to cross the BBB to some extent, thus reducing lysosomal storage in brain microglial cells. "
12/01/2006 - "In this proof of concept study, we explore whether glial precursors derived from murine ES cells (ESGPs) and engineered to overexpress human arylsulfatase A (hASA) can cross-correct the metabolic defect in an animal model of metachromatic leukodystrophy (MLD). "
11/01/2005 - "In this multicentre study, we examined the prevalence of two mutations in the arylsulfatase A (ARSA) gene, i.e., c.459+1G>A and p.P426L, in 384 unrelated European patients presenting with different types of metachromatic leukodystrophy (MLD). "
12/23/1985 - "Studies in metachromatic leukodystrophy: XV. Purification of normal and mutant arylsulfatase A from human liver."
12/31/1991 - "More detailed statistical analysis of the results indicates that determination of the serum concentration of arylsulfatase A might be helpful in the diagnosis of lung (59% sensitivity, 82% specificity) and central nervous system cancer (60% sensitivity, 82% specificity). "
06/01/2000 - "To understand the significance of any changes in the glycosylation of arylsulfatase A in cancer, it is important to know the structure of its carbohydrate component in normal tissue. "
06/01/2000 - "It has been shown that the concentration of arylsulfatase A increases in the body fluids of patients with some forms of cancer, and the carbohydrate component of arylsulfatase A synthesized in tumor tissues and transformed cells undergoes increased sialylation, phosphorylation and sulfation. "
03/01/1997 - "To understand the significance of any changes in glycosylation of arylsulfatase A in cancer, it is important to know the structure of its carbohydrate component in normal tissue. "
03/01/1997 - "It has been shown that the concentration of arylsulfatase A increases in the body fluids of patients with some forms of cancer and the carbohydrate component of arylsulfatase A synthesized in tumor tissues and transformed cells undergoes increased sialylation, phosphorylation and sulfation. "
|3.||Nervous System Diseases (Neurological Disorders)
09/01/1991 - "Reduced activity of arylsulfatase A and predisposition to neurological disorders: analysis of 140 pediatric patients."
07/01/2014 - "Arylsulfatase A (ASA) deficiency is the cause of metachromatic leucodystrophy (MLD), a lysosomal storage disease associated with severe neurological disorders. "
04/01/2009 - "To assess the efficacy of long-term ERT in metachromatic leukodystrophy (MLD), an LSD with prevailing nervous system disease, we treated immunotolerant arylsulfatase A (ASA) knockout mice with 52 doses of either 4 or 50 mg/kg recombinant human ASA (rhASA). "
|4.||Mucopolysaccharidosis VI (Syndrome, Maroteaux-Lamy)
01/01/1981 - "An improved method has been developed for the detection of heterozygotes for feline and human mucopolysaccharidosis VI. Arylsulfatase-A and -B activities were assayed in leukocyte extracts following separation of the enzymes by batch chromatography on DEAE cellulose. "
10/31/1991 - "The enzyme activity of arylsulfatase A and arylsulfatase B was studied in Epstein-Barr virus-transformed lymphoid cell lines established from control individuals and patients affected with metachromatic leukodystrophy, mucopolysaccharidosis type VI (or Maroteaux-Lamy syndrome) and multiple sulfatase deficiency. "
|5.||Memory Disorders (Memory Loss)
|3.||Lysergic Acid Diethylamide (LSD)
|5.||Complementary DNA (cDNA)
|6.||N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B)
|9.||Molecular Chaperones (Chaperone, Molecular)
|10.||Interleukin-8 (Interleukin 8)
|1.||Enzyme Replacement Therapy
|3.||Tissue Therapy (Cell Therapy)